The halls of Congress recently served as a high-stakes arena where the future of American public health was debated against the backdrop of a massive fiscal restructuring effort led by Secretary Robert F. Kennedy Jr. This marathon session of congressional hearings, spanning multiple days of intense
James Maitland has spent decades at the intersection of healthcare infrastructure and pharmaceutical regulation, witnessing the evolution of safety-net programs from modest beginnings to the multi-billion-dollar engines they are today. As the 340B drug discount program faces a pivotal crossroads,
The federal government is currently funneling an estimated $76 billion in annual overpayments to private insurance companies, a staggering sum that now surpasses the total operating budgets of several major agencies. As Medicare Advantage now covers more than half of all eligible seniors, a rare
Understanding the Judicial Shield Around Arbitration Awards The escalating financial stakes in the multi-billion dollar healthcare reimbursement market have reached a boiling point as federal courts begin to cement the finality of independent arbitration awards. This development marks a significant
The transformation of the 340B drug pricing program from a targeted federal safety net into a massive, multi-billion-dollar profit center has ignited a fierce legislative debate within the halls of Congress. Originally established to assist healthcare providers in stretching scarce federal
The invisible bridge connecting a laboratory's surgical breakthrough to a senior citizen's recovery room is built almost entirely of government reimbursement codes and bureaucratic approvals. For years, the federal government provided a "fast track" for cutting-edge medical devices, but a major
